Introduction:
Intracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic peptides. The company plans to use the funds to advance its early preclinical programs and expand its discovery platform.
- New investors, including Columbus Venture Partners and British Patient Capital, joined lead investor Pfizer Ventures in the financing round.
- Curve Therapeutics has developed the intracellular Microcycle screening platform, which has identified cyclic peptides that target various intracellular protein targets involved in cancer.
- The company plans to use the funds to advance its early preclinical programs into clinical trials and expand its discovery platform to target more challenging and complex intracellular protein targets.
- Curve Therapeutics previously closed a deal with Merck Sharpe & Dohme to discover and validate modulators of therapeutic targets using its Microcycle technology.
- The company’s functional drug discovery platform was developed by Prof. Dr Ali Tavassoli’s group at the University of Southampton.
Conclusion:
Curve Therapeutics has secured £40.5m in funding to advance its pipeline of small cyclic peptides. The funds will be used to progress early preclinical programs into clinical trials and expand the company’s discovery platform to target more challenging intracellular protein targets. This investment will provide support for Curve Therapeutics’ innovative approach to intracellular cancer target screening and its goal of developing new therapies for cancer treatment.
